ArticleAdvances in radiation oncology2026
Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: For locoregionally advanced hypopharyngeal carcinoma (LAHPC), organ preservation via induction chemotherapy followed by concurrent chemoradiotherapy (IC-CCRT) is a key strategy, yet robust data from homogeneous cohorts treated with modern radiation therapy are scarce. This prospective study evaluated the efficacy and safety of IC-CCRT in a contemporary LAHPC cohort. Methods and Materials: From January 2015 to December 2021, 259 patients with LAHPC receiving curative-intent IC-CCRT with intensity-modulated radiation therapy were enrolled. Endpoints included survival with functional larynx (SFL), overall survival, progression-free survival, and disease control measures. Results: The 5-year rates for SFL, overall survival, progression-free survival, local failure-free survival, locoregional failure-free survival, and distant metastasis-free survival (DMFS) were 49.9%, 51.5%, 43.3%, 50.2%, 48.6%, and 46.4%, respectively. Outcomes declined sharply with advancing American Joint Committee on Cancer (AJCC) stage. The 5-year SFL was 89.0% for stage III, 47.0% for stage IVA (hazard ratio [HR] 4.02; 95% CI, 1.66-9.77; Conclusions: IC-CCRT provides meaningful survival and larynx preservation in LAHPC, but efficacy is highly dependent on AJCC stage and T classification. Patients with T4b tumors have particularly poor outcomes. The developed nomogram offers a practical tool for individual outcome prediction. Treatment should be individualized, balancing survival benefits against significant treatment-related toxicities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.